Does State Medicaid Cover Praluent (Alirocumab)?

How State Medicaid Programs Handle Praluent Coverage

Medicaid is administered at the state level, which means no single national formulary governs alirocumab access. Each state's Medicaid program (or its managed care organizations) maintains its own preferred drug list (PDL) and utilization management criteria. The result is a patchwork: some states place Praluent on a specialty tier with relatively straightforward prior authorization, while others impose multiple layers of step therapy and documentation before a prescription is approved.

Federal law requires state Medicaid programs to cover all FDA-approved drugs from manufacturers that participate in the Medicaid Drug Rebate Program, and Regeneron/Sanofi (the makers of Praluent) do participate. This means states cannot categorically refuse to cover alirocumab. They can, and nearly all do, impose prior authorization and clinical criteria that must be met before a claim is paid [1]. According to the Medicaid Drug Rebate Program statute, participating manufacturers must offer mandatory rebates to state Medicaid agencies, which brings the effective net cost below the $580 list price.

A 2019 analysis published in JAMA Cardiology found that Medicaid prior authorization denial rates for PCSK9 inhibitors exceeded 50% in some states, with processing times stretching to 30 days or longer [2]. These barriers have loosened somewhat since Praluent's list price was reduced by Sanofi/Regeneron in 2024, but significant state-to-state variation persists.

Prior Authorization Criteria: What States Typically Require

Prior authorization is the single biggest barrier between a Praluent prescription and pharmacy pickup. While exact criteria differ, a recognizable pattern emerges across most state Medicaid formularies.

The prescribing provider must usually document one of the following diagnoses: heterozygous familial hypercholesterolemia (HeFH), homozygous familial hypercholesterolemia (HoFH), or clinical ASCVD defined as a history of myocardial infarction, stroke, or peripheral arterial disease. Many states also accept primary hyperlipidemia with very high cardiovascular risk when LDL-C remains above a threshold (commonly 70 mg/dL for ASCVD or 100 mg/dL for HeFH) despite maximally tolerated statin therapy [3].

Documentation typically required includes:

• Baseline and current LDL-C values. Most states want two fasting lipid panels separated by 4 to 12 weeks.
• Statin trial history. The prescriber must show the patient tried and failed, or is intolerant to, at least one high-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for a minimum of 8 to 12 weeks.
• Ezetimibe trial. A growing number of states (roughly 60% as of 2025) require documented use of ezetimibe 10 mg in addition to statin therapy before approving a PCSK9 inhibitor.
• Specialist involvement. Some states mandate that alirocumab be prescribed or co-managed by a cardiologist, endocrinologist, or lipidologist.

The FDA-approved prescribing information for Praluent supports use as an adjunct to diet and maximally tolerated statin therapy, and state criteria largely mirror this label language [4].

Step Therapy Requirements Across State Medicaid Programs

Step therapy (sometimes called "fail first") is distinct from prior authorization, though states often bundle the two together. Where prior authorization asks the prescriber to prove clinical need, step therapy dictates the sequence of drugs that must be tried before the target drug is authorized.

For alirocumab, the most common step therapy ladder looks like this:

Step 1: High-intensity statin (atorvastatin 40-80 mg or rosuvastatin 20-40 mg) for 8-12 weeks. Step 2: Add ezetimibe 10 mg to the statin regimen for an additional 8-12 weeks. Step 3: If LDL-C remains above goal, Praluent or evolocumab (Repatha) may be authorized.

Some states compress this into two steps by allowing statin plus ezetimibe combination therapy from the start. Others add a fourth step requiring the prescriber to try bempedoic acid (Nexletol) or inclisiran (Leqvio) before approving a PCSK9 monoclonal antibody. In the ODYSSEY OUTCOMES trial (N=18,924), alirocumab 75-150 mg every two weeks reduced major adverse cardiovascular events by 15% (HR 0.85 to 95% CI 0.78-0.93) in patients with recent acute coronary syndrome already on high-intensity statin therapy [1]. This evidence base is the primary justification providers cite when requesting step therapy exceptions.

A practical point: statin intolerance can sometimes bypass step therapy entirely. If a patient has documented myalgias, elevated creatine kinase, or rhabdomyolysis attributed to two or more statins, many states allow direct authorization of alirocumab without completing the full step ladder. The 2018 AHA/ACC Cholesterol Guideline specifically recognizes PCSK9 inhibitors as appropriate for statin-intolerant patients with ASCVD or HeFH whose LDL-C remains above 70 mg/dL [5].

How to Appeal a Medicaid Denial of Praluent

A denied prior authorization is not the end of the process. Federal Medicaid regulations guarantee every beneficiary the right to a fair hearing when a service is denied, reduced, or terminated. The appeal pathway follows a general sequence, though timelines vary by state.

Internal appeal (first level). After receiving a denial letter, the patient or prescriber submits additional clinical documentation to the Medicaid managed care plan (if enrolled in managed care) or directly to the state fee-for-service Medicaid office. Most states allow 30 to 60 days from the denial notice to file. Including peer-reviewed evidence, such as the ODYSSEY OUTCOMES data showing a 24% reduction in all-cause mortality in patients with baseline LDL-C of 100 mg/dL or higher [1], strengthens the appeal.

External review or state fair hearing (second level). If the internal appeal is denied, the beneficiary can request a state fair hearing. This is an administrative law proceeding where an impartial hearing officer reviews the medical evidence. The beneficiary, a representative, or the prescribing physician can present testimony. Fair hearing decisions are legally binding on the Medicaid agency.

Expedited appeal. If the prescriber certifies that standard appeal timelines could seriously jeopardize the patient's life or health, most states must process an expedited review within 72 hours. For a patient with recent ACS and persistently elevated LDL-C, this expedited pathway may be appropriate.

Key documentation to include in any appeal:

• Complete lipid panel history showing LDL-C trajectory on current therapy
• Dates, doses, and outcomes of each statin and ezetimibe trial
• Clinical rationale explaining why continued delay poses cardiovascular risk
• Relevant clinical trial citations (ODYSSEY OUTCOMES [1], ODYSSEY LONG TERM [6])
• If applicable, genetic testing confirming familial hypercholesterolemia

A 2021 study in Circulation: Cardiovascular Quality and Outcomes found that among patients who appealed PCSK9 inhibitor denials, approximately 40-50% were eventually approved on appeal, and the median time from initial prescription to final approval exceeded 60 days [7].

Praluent Formulary Placement and Preferred Status

Formulary tier placement determines the patient's out-of-pocket cost, though for Medicaid beneficiaries copayments are capped at nominal amounts (typically $0-$4 for preferred brands and $0-$8 for non-preferred brands, depending on the state and income level).

Most state Medicaid programs place Praluent on a specialty or non-preferred brand tier. In states where the Medicaid program or its pharmacy benefit manager has negotiated supplemental rebates with Sanofi/Regeneron, Praluent may hold preferred status over evolocumab (Repatha), or the reverse may be true. Texas Medicaid's Vendor Drug Program, for example, has historically preferred whichever PCSK9 inhibitor offers the larger supplemental rebate, and this preferred status can shift during annual rebate negotiations.

The practical difference for patients: a preferred PCSK9 inhibitor may require a simpler prior authorization form and fewer step therapy hurdles than the non-preferred option. If your state's Medicaid formulary prefers evolocumab over alirocumab, switching to the preferred agent is sometimes the fastest path to approval, though clinical differences between the two drugs are minimal. Both reduce LDL-C by 50-60% on average, and both have outcomes trial evidence supporting cardiovascular event reduction [1][8].

To check your state's current formulary, search "[state name] Medicaid preferred drug list" or contact the Medicaid pharmacy help desk listed on your benefits card.

Manufacturer Savings and Patient Assistance Programs

Medicaid beneficiaries cannot use manufacturer copay savings cards. Federal anti-kickback statutes prohibit copay assistance for patients covered by federal healthcare programs, including Medicaid [9]. This restriction applies to the Praluent copay card that Sanofi/Regeneron offers to commercially insured patients.

Patients do have other options. Sanofi/Regeneron operates the Praluent MyWay patient assistance program, which provides the medication at no cost to qualifying uninsured or underinsured patients. Medicaid beneficiaries who are denied coverage and have exhausted appeals may be eligible, though program rules change periodically. The Regeneron Patient Assistance Program application is available through the prescriber's office.

Separately, nonprofit organizations such as the Patient Access Network (PAN) Foundation and the HealthWell Foundation have historically offered grants covering specialty drug costs for cardiovascular conditions. Eligibility depends on income (typically at or below 400% of the federal poverty level) and fund availability.

Clinical Evidence Supporting Medicaid Coverage of Alirocumab

State Medicaid programs base their coverage criteria on the strength of clinical evidence. Two large-scale trials form the backbone of alirocumab's evidence base.

ODYSSEY OUTCOMES randomized 18,924 patients with recent acute coronary syndrome (1-12 months prior) to alirocumab 75-150 mg or placebo every two weeks, on top of high-intensity statin therapy. At a median follow-up of 2.8 years, alirocumab reduced the composite of coronary heart disease death, nonfatal MI, ischemic stroke, or unstable angina requiring hospitalization by 15% (HR 0.85 to 95% CI 0.78-0.93, P=0.0003) [1]. A prespecified analysis found a 29% reduction in all-cause mortality among patients whose baseline LDL-C was 100 mg/dL or higher.

ODYSSEY LONG TERM enrolled 2,341 patients at high cardiovascular risk with LDL-C of 70 mg/dL or above despite maximally tolerated statin therapy. Alirocumab 150 mg every two weeks reduced LDL-C by 61% at 24 weeks compared to placebo. Post-hoc analysis showed a 48% reduction in major adverse cardiovascular events, though this was an exploratory endpoint [6].

The 2018 AHA/ACC Multisociety Cholesterol Guideline gives a Class IIa recommendation (Level of Evidence: A) for adding a PCSK9 inhibitor in patients with clinical ASCVD at very high risk whose LDL-C remains at or above 70 mg/dL on maximally tolerated statin plus ezetimibe therapy [5]. The 2022 ACC Expert Consensus Decision Pathway reaffirmed this position, adding that PCSK9 inhibitors should be considered earlier in therapy for patients with baseline LDL-C of 190 mg/dL or higher suggestive of familial hypercholesterolemia [10].

State-by-State Variation: What Drives the Differences

Three factors explain most of the variation in Medicaid coverage of Praluent across states.

Supplemental rebate agreements. States that negotiate larger rebates with Sanofi/Regeneron may impose fewer barriers because the net cost to the program is lower. These agreements are confidential, so the exact rebate amount is not public, but their effect on formulary placement is visible.

Managed care penetration. In states where most Medicaid beneficiaries are enrolled in managed care organizations (MCOs), coverage decisions are made by the MCO, not the state directly. A single state may have five or more MCOs, each with different prior authorization forms, different preferred PCSK9 inhibitors, and different step therapy protocols. California's Medi-Cal program, for instance, operates with multiple managed care plans that set their own specialty drug criteria within state-defined guardrails.

Budget constraints and disease burden. States with higher rates of cardiovascular disease and limited pharmacy budgets may impose stricter utilization controls on high-cost specialty drugs. A single Medicaid beneficiary on Praluent at list price ($6,960 per year before rebates) represents a significant line item. The cost-effectiveness analysis by the Institute for Clinical and Economic Review (ICER) initially estimated the value-based price for PCSK9 inhibitors at $2,300-$3,400 per year, though the 2024 list price reduction brought Praluent closer to that range [11].

Practical Tips for Patients and Prescribers

Getting Praluent approved through Medicaid requires a systematic approach. Start by confirming the current formulary status and prior authorization form for your specific Medicaid plan. Call the number on the back of the Medicaid card or check the plan's online formulary search tool.

Prescribers should document the clinical rationale thoroughly on the first submission. Include fasting lipid panels, statin trial dates and doses, reasons for intolerance (if applicable), ezetimibe trial results, and the specific cardiovascular risk category (HeFH, clinical ASCVD with very high risk features, or primary prevention with LDL-C persistently at or above 190 mg/dL). Incomplete documentation is the most common reason for initial denial.

If the initial prior authorization is denied, file the appeal within the timeframe specified in the denial letter (usually 30-60 days). Attach the ODYSSEY OUTCOMES publication [1], the relevant AHA/ACC guideline recommendation [5], and an updated clinical note from the prescribing physician.

Patients enrolled in Medicaid managed care have the right to request a formulary exception if Praluent is not on the MCO's preferred drug list. This process runs parallel to prior authorization and may be submitted simultaneously. The median time to PCSK9 inhibitor approval on Medicaid was 45 days in a 2022 multistate analysis, so plan for a 4-8 week timeline from first prescription to pharmacy dispensing [12].